QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies …
Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially …
Overview Despite significant advances in understanding and treating nervous system disorders, millions of people worldwide continue to live with neurodegenerative …